Skip to main content
Premium Trial:

Request an Annual Quote

UPDATE: Roche Seeks to Extend Antitrust Waiting Period for Illumina Bid

This article has been updated from a previous version to clarify that Roche is seeking to extend the antitrust waiting period for its bid, not the timeline for the tender offer.

NEW YORK (GenomeWeb News) – Roche is seeking to extend the antitrust waiting period required for its $5.7 billion hostile bid for Illumina, it said in a document filed with the US Securities and Exchange Commission.

In the filing, Roche said it will file necessary paperwork on Feb. 27 to extend the required waiting period under the Hart-Scott-Rodino at to expire at the end of the day March 13. The US Antitrust Division or Federal Trade Commission may further extend the waiting period, Roche noted in the filing.

Roche is offering $44.50 per share of Illumina's stock. Illumina has rejected the bid and implemented a poison pill plan. Roche named its nominees for Illumina's board a few weeks ago as part of its hostile bid.

Shareholders have filed a lawsuit against Illumina alleging conflict of interest and breach of fiduciary responsibilities.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.